EDBI Logo
|  

Cell Therapeutics Enters Into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis

Related Posts

Forging Resilience in Both Worlds

  • 29 02 2024
  • |
Read More

The Harvard Founder Who Did the Opposite of What He Learnt

  • 29 02 2024
  • |
Read More

Bounce Back Stronger: 4 Ways to Turn Failure into Fuel for Success

  • 29 02 2024
  • |
Read More

Silicon Valley doesn’t have all the Answers

  • 29 02 2024
  • |
Read More

From Burning to Turning to Earning. The Inside Story of a Business Resurrection.

  • 29 02 2024
  • |
Read More

EDBI: A look back at 2023

  • 16 02 2024
  • |
Read More

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

Linkedin Youtube

© 2023 EDBI. All rights reserved.